88IV - PR Newswire Asia's news - Biotechnology

< Previous page

| Title only | Print

Next page >

Caliway's CBL-514 Combination Therapy Cleared by U.S. FDA for Phase 2 Trial; Pivotal Phase 3 Trial SUPREME-01 Initiates Enrollment FDA IND Clearance for CBL-0201WR —Caliway has cleared its Investigational New Drug application for CBL-0201WR, a Phase 2 trial evaluating CBL-514 in combination with tirzepatide. U.S. IRB Approval ... 2026-08-26T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
HaemaLogiX Announces Major Milestone with First Patient Successfully Dosed with KMCAR™ T-Cell KEY POINTS ... 2026-08-26T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Metabolon Completes Landmark Global Health Pilot Advancing Women's and Infant Health Innovative sample collection methods developed through Gates Foundation-funded grant enable high-quality metabolomics biomarker discovery in populations from low- and middle-income countries ... 2026-08-25T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
WuXi Biologics Reports Strong Profitable Growth in H1 2026 Revenue of RMB 11.8 billion grew 18.4% YoY (23.4% YoY in USD) IFRS gross profit margin expanded to 46.2% (+350 bps YoY) and adjusted gross profit margin expanded to 48.4% (+280 bps YoY), despite foreign ... 2026-08-25T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Fosun Pharma Announces 2026 Interim Results Globalization Accelerates Value Realization of Innovative Drugs ... 2026-08-25T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Innovent Announces 2026 Interim Results and Business Updates Transforming from Regional Leader to Global Premier: ... 2026-08-25T Biotechnology Health Care/Hospital Medical Equipment Medical/Pharmaceuticals
Haisco enters into Exclusive License Agreement with new US venture founded by Population Health Partners and ARCH Venture Partners BEIJING , Aug. 25, 2026 /PRNewswire/ -- On August 25, Haisco Pharmaceutical Group Co., Ltd. ("Haisco") (Ticker Code: 002653) announced that it has entered into an exclusive licensing ... 2026-08-25T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Cambrex High Point Completes FDA, PMDA and TGA Pre-Approval Inspections, Advancing Commercial Manufacturing Capabilities EAST RUTHERFORD, N.J. , Aug. 25, 2026 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), today announced the successful completion of three Pre-Approval ... 2026-08-25T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Senhwa Completes Enrollment in Phase 1b CX-5461 Expansion Trial; CSR Expected in Q1 2027 TAIPEI , Aug. 25, 2026 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492) today announced that it has completed enrollment in its Phase 1b expansion trial evaluating pidnarulex (CX-5461) monotherapy ... 2026-08-25T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Antengene Receives Clinical Trial Approval in Australia for Phase I ATTRACT Study of ATG-201 (CD19 x CD3 TCE) in B Cell-related Autoimmune Diseases SHANGHAI and HONG KONG , Aug. 25, 2026 /PRNewswire/ -- Antengene Corporation Limited (" Antengene ", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company ... 2026-08-25T Biotechnology Health Care/Hospital Medical/Pharmaceuticals

< Previous page

Next page >

88iv | Home | Login

Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer

Copyright (C) 2026

Suntek Computer Systems Limited.

All rights reserved